-
公开(公告)号：US20160229890A1
公开(公告)日：2016-08-11
申请号：US15021889
申请日：2014-08-11
申请人： Soligenix, Inc.
发明人： Oreola Donini , Annett Rozek , Jackson Lee , John North , Michael Abrams
IPC分类号： C07K7/06 , A61K31/573 , A61K45/06 , A61K38/08
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
摘要翻译： 化疗引起的粘膜炎，辐射诱导的粘膜炎，中性粒细胞减少性感染和结肠炎模型中获得的临床前数据表明口腔粘膜炎是先天性防御调节剂（IDR）肽的有前途的指标。 IDR在小鼠和仓鼠粘膜炎模型中获得的临床前效力结果表明，取决于化疗或放射线暴露的持续时间，每三天给药应能够以7至14次剂量覆盖粘膜炎“窗口”。 IDRs还显示了化疗引起的口腔和胃肠粘膜炎的小鼠模型的功效，与化疗和/或辐射损伤的先天免疫应答的反应一致。 IDRs在各种鼠感染模型中，在存在或不存在抗生素治疗的同时，也有效减少细菌负担并改善生存。
-
公开(公告)号：US10253068B2
公开(公告)日：2019-04-09
申请号：US15848746
申请日：2017-12-20
申请人： Soligenix, Inc.
发明人： Oreola Donini , Annett Rozek , Jackson Lee , John North , Michael Abrams
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
-
公开(公告)号：US20180170964A1
公开(公告)日：2018-06-21
申请号：US15848746
申请日：2017-12-20
申请人： Soligenix, Inc.
发明人： Oreola Donini , Annett Rozek , Jackson Lee , John North , Michael Abrams
IPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/11
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
-
公开(公告)号：US11311598B2
公开(公告)日：2022-04-26
申请号：US16379101
申请日：2019-04-09
申请人： Soligenix, Inc.
发明人： Oreola Donini , Annett Rozek , Jackson Lee , John North , Michael Abrams
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
-
公开(公告)号：US20200323946A1
公开(公告)日：2020-10-15
申请号：US16379101
申请日：2019-04-09
申请人： Soligenix, Inc.
发明人： Oreola Donini , Annett Rozek , Jackson Lee , John Carpenter , Michael Abrams
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
-
公开(公告)号：US09850279B2
公开(公告)日：2017-12-26
申请号：US15021889
申请日：2014-08-11
申请人： Soligenix, Inc.
发明人： Oreola Donini , Annett Rozek , Jackson Lee , John North , Michael Abrams
CPC分类号： C07K7/06 , A61K31/573 , A61K38/08 , A61K45/06 , C07K5/1019
摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.013 秒)
